Session » Quality Measures and Quality of Care - Poster II

Date: Monday, November 14, 2016

Time: 9:00AM-11:00AM

Meeting: 2016 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1424

Acceptability of a Connected Activity Tracker in 92 Patients with Rheumatoid Arthritis (RA) or Axial Spondyloarthritis (axSpA): A 3-Months Study

9:00AM-11:00AM: Abstract Number: 1414

Access to an Active, Interactive Self-Assessment e-Health Platform Improves Patient-Physician Communication in Rheumatoid Arthritis: Results of a Randomized Controlled Trial Including 320 Patients over 1 Year

9:00AM-11:00AM: Abstract Number: 1430

Adherence to the International Consensus Quality Indicators for Longitudinal Health Maintenance and Preventative Care in a Pediatric Rheumatology Clinic

9:00AM-11:00AM: Abstract Number: 1411

An Electronic MDHAQ (multidimensional health assessment questionnaire) Beyond an Electronic RAPID (routine assessment of patient index data): 21.3% of Rheumatoid Arthritis Patients Identified As Having Secondary Fibromyalgia Versus 3.5% By Clinicians

9:00AM-11:00AM: Abstract Number: 1417

Back to Feeling Normal Again: Patients with Rheumatoid Arthritis in Remission

9:00AM-11:00AM: Abstract Number: 1407

Disease Activity Trackers to Support Treat to Target Strategies: A Needs Assessment Survey

9:00AM-11:00AM: Abstract Number: 1413

Establishing Clinical Severity for Patient Reported Outcomes Measurement Information System Measures in Adult Patients with Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 1431

Estimates of Global Status By Physicians and Patients Are More Likely to be Discordant in Osteoarthritis Than in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1422

Identifying Generic and Specific Patients’ Perspectives on Disease- and Treatment-Related Issues in Rheumatoid Arthritis, Psoriatic Arthritis, and Psoriasis: A Qualitative Concept Mapping Study

9:00AM-11:00AM: Abstract Number: 1408

Impact of Participation in the Adalimumab (Humira) Patient Support Program on Patient Reported Outcomes Among Patients with Rheumatoid Arthritis: Passion Study

9:00AM-11:00AM: Abstract Number: 1415

Impact of the Clinical Disease Activity Index to Treat to Target Rheumatoid Arthritis in the Ambulatory Setting

9:00AM-11:00AM: Abstract Number: 1409

Increase in the Use of Validated Disease Activity Scores in Current Daily Clinical Practice Compared to 2007

9:00AM-11:00AM: Abstract Number: 1410

Is the Self-Assessment of Disease Activity (auto-DAS28) By Patients a Feasible and Acceptable Measure over the Long Term in Rheumatoid Arthritis (RA)? Three-Year Follow-up of a Nurse-Led Program in 771 Patients with Established RA

9:00AM-11:00AM: Abstract Number: 1428

Patient Attitudes Towards Being Prescribed Biosimilars in Inflammatory Autoimmune Diseases in Germany

9:00AM-11:00AM: Abstract Number: 1429

Patient-Reported Outcomes Measures and Economical Burden of Patients with Ankylosing Spondylitis in a Chinese Prospective Cohort with Smart Management System for Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 1405

Quality Measures in High Priority Rheumatologic Diseases: A Systematic Literature Review and Analysis

9:00AM-11:00AM: Abstract Number: 1421

Responsiveness of Lupus Impact Tracker Among Chinese Patients with Lupus

9:00AM-11:00AM: Abstract Number: 1418

Rheumatologist: If You Fell Ill with Seropositive Active Rheumatoid Arthritis Yourself, What to Do!

9:00AM-11:00AM: Abstract Number: 1433

Self-Perception Reporting to Healthcare Professionals: Do Individuals with Systemic Sclerosis Report Quality of Life Changes Accurately?

9:00AM-11:00AM: Abstract Number: 1416

Sustained Improvement in Documentation of Disease Activity Measurement As a Quality Improvement Project at an Academic Rheumatology Clinic

9:00AM-11:00AM: Abstract Number: 1403

Systematic Appraisal of the American College of Rheumatology Clinical Practice Guidelines

9:00AM-11:00AM: Abstract Number: 1404

Systematic Review and Appraisal of Quality Measures for Inflammatory Arthritis

9:00AM-11:00AM: Abstract Number: 1432

The EULAR Systemic Sclerosis Impact of Disease Score – a New Patient-Reported Outcome Measure for Patients with Systemic Sclerosis Under Development

9:00AM-11:00AM: Abstract Number: 1427

The Importance of Outcome Measures in Ankylosing Spondylitis – Validity of the Routine Assessment of Patient Index Data 3 in a Real World Cohort

9:00AM-11:00AM: Abstract Number: 1406

Towards Harmonized Data Collection in Rheumatoid Arthritis (RA): The EULAR Task Force for Standardizing a Minimum Data Collection for RA Observational Research

9:00AM-11:00AM: Abstract Number: 1423

Using Self-Reported Patient Experiences to Evaluate Patient Reported Outcomes (PRO) Instruments: Learnings from Digital Patient Communities in Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1426

Using Self-Reported Patient Experiences to Understand Patient Burden: Learnings from Digital Patient Communities in Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 1425

Validation of a Patient Reported Experience Measure (PREM) in Patients with Axial Spondyloarthropathies (AxSpA)

9:00AM-11:00AM: Abstract Number: 1420

Validation of Lupuspro V1.8, Disease Targeted Patient Reported Outcome for Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1412

Validation of the Danish Version of the Stanford Health Assessment Questionnaire Disability Index and Determination of the Minimal Clinically Important Difference in a Cohort of Rheumatoid Arthritis Patients Using the Rasch Measurement Model

9:00AM-11:00AM: Abstract Number: 1419

Validation of the French Version of Lupus Patient Reported Outcome (LupusPRO), a Disease-Specific Patient Reported Outcome for Lupus Patients

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.